NicOx completes enrollment in hypertension trial

By Elaine Rigoli

Tampa, Fla., Aug. 3 - NicOx SA said it completed subject enrollment ahead of schedule in the ambulatory blood-pressure monitoring trial for naproxcinod (HCT 3012).

Results are anticipated in the fourth quarter of 2006.

The company said naproxcinod is a proprietary COX-inhibiting nitric oxide-donator, which is in phase 3 clinical development for the treatment of the signs and symptoms of osteoarthritis.

NicOx said it aims to develop naproxcinod as the drug-of-choice for the treatment of osteoarthritis, especially in those patients with co-existing hypertension, based on nitric oxide's ability to improve blood-pressure control.

The trial has a double-blind, randomized, cross-over design, and subjects, between the ages of 50 and 75, have been randomized to either one of two groups: about 60 are being treated with 750 mg of naproxcinod twice-daily for 14-days followed by 500 mg of naproxen twice-daily for 14 days and about 60 subjects are receiving the compounds in the opposite order.

NicOx is a product-driven biopharmaceutical company with headquarters in Sophia-Antipolis, France.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.